Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

Romain Daillère, Bertrand Routy, Anne Gaëlle Goubet, Alexandria Cogdill, Gladys Ferrere, Carolina Alves-Costa Silva, Aurélie Fluckiger, Pierre Ly, Yacine Haddad, Eugenie Pizzato, Cassandra Thelemaque, Marine Fidelle, Marine Mazzenga, Maria Paula Roberti, Cléa Melenotte, Peng Liu, Safae Terrisse, Oliver Kepp, Guido Kroemer, Laurence ZitvogelLisa Derosa

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    9 Citations (Scopus)

    Résumé

    Accumulating evidence from preclinical studies and human trials demonstrated the crucial role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade. In summary, it appears that a diverse intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota composition that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. In this review, we explore preclinical and translational studies highlighting how eubiotic and dysbiotic microbiota composition can affect progression-free survival in cancer patients.

    langue originaleAnglais
    Numéro d'article1794423
    journalOncoImmunology
    Volume9
    Numéro de publication1
    Les DOIs
    étatPublié - 1 janv. 2020

    Contient cette citation